On September 10, an expert panel of the National Heart, Lung, and Blood Institute (NHLBI) released new guidelines for managing sickle cell disease (SCD), stressing the use of the drug hydroxyurea and transfusions for many with the genetic disorder. More than 12,000 scientific articles were reviewed and evidence was examined in order to create this new blueprint for care. A summary of the new guidelines were published in the Journal of the American Medical Association. The report is intended to assist healthcare professionals in their management and treatment of the disease among their infant, adolescent, and adult sickle cell disease patients. Click on the links below to read and download the report, and learn more about these guidelines and other SCD resources.
READ the summary article in JAMA
(Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members. JAMA. 2014;312(10):1033-1048. doi:10.1001/jama.2014.10517) /p>
For additional resources on Sickle Cell Disease from NHLBI, click here.